Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease
Saiko Kurosawa(Kubota (Japan)), Yoshiko Atsuta(The Japanese Data Center for Hematopoietic Cell Transplantation), Koichi Miyamura, Yoshihiro Inamoto, Tadakazu Kondo(Kyoto University Hospital), Takanori Teshima(Hokkaido University Hospital), Yukari Umemoto(Osaka City University), Shinichiro Okamoto(Keio University), Takehiko Mori(Keio University), Satoshi Takahashi(Sapporo Medical University), Shuichi Taniguchi(Hamanomachi Hospital), Heiwa Kanamori(Kanagawa Prefectural Hospital Organization), Takuhiro Yamaguchi(Tohoku University), Takuya Yamashita(National Cancer Center), Akio Kohno(Konan Kosei Hospital), Takahiro Fukuda(Takarazuka City Hospital), Atsumi Yanagisawa(The Japanese Data Center for Hematopoietic Cell Transplantation), Kumi Oshima(Jyoban Hospital), Yoshinobu Kanda(Jichi Medical University)
Cited by 116
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2020|739
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|435